February 26, 2024 10:42 AM EST

Milestone’s plans to resubmit heart drug; Alvotech’s $166M offer; Vaccine biotech raises $11M

Jaimy Lee

Deputy Editor

Kyle LaHucik

Senior Reporter

Milestone Pharmaceuticals details plan to resubmit etripamil to the FDA in Q2: For its experimental treatment for paroxysmal supraventricular tachycardia, the company

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Milestone’s plans to resubmit heart drug; Alvotech’s $166M offer; Vaccine biotech raises $11M

Jaimy Lee

Deputy Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Mile­stone’s plans to re­sub­mit heart drug; Alvotech’s $166M of­fer; Vac­cine biotech rais­es $11M

Deputy Editor

Senior Reporter

Sign up to read this article for free.

Milestone’s plans to resubmit heart drug; Alvotech’s $166M offer; Vaccine biotech raises $11M